Loading...

MedXY News - MASLD

MedXY AI/MedXY News/Tag: MASLD

MedXY News

EnglishTag

MASLD

42 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds

Lower-Dose Vitamin E Works as Well as Higher Doses in MASLD, VEDS Trial Finds

In adults with suspected MASH, 200 IU/day vitamin E lowered ALT as effectively as 400 IU/day and 800 IU/day over 24 weeks, with no short-term safety signal, supporting lower-dose use if vitamin E is chosen.

Section: GastroenterologyJun 20, 2026

Adolescent MASLD Plus PCOS Signals a Higher-Risk Cardiometabolic Trajectory Into Adulthood

Adolescent MASLD Plus PCOS Signals a Higher-Risk Cardiometabolic Trajectory Into Adulthood

In the Raine Study, adolescents with both MASLD and PCOS had a substantially worse cardiometabolic profile by age 27 than peers with either condition alone, highlighting a high-risk subgroup that may warrant earlier metabolic surveillance.

Section: Diabetes & EndocrinologyMay 28, 2026

HSP72-PRDX6 Control of PINK1 Ubiquitination Emerges as a New Mitophagy Axis in MASLD

HSP72-PRDX6 Control of PINK1 Ubiquitination Emerges as a New Mitophagy Axis in MASLD

A new Hepatology study identifies an HSP72–PRDX6 pathway that restores PINK1/Parkin mitophagy, reduces hepatic steatosis, and worsens MASLD when disrupted in mice and hepatocytes.

Section: GastroenterologyMay 1, 2026

Oral Glucose Absorption Enhanced in Early Metabolic Dysfunction-Associated Steatotic Liver Disease

Oral Glucose Absorption Enhanced in Early Metabolic Dysfunction-Associated Steatotic Liver Disease

New research reveals accelerated glucose absorption in early MASLD patients, independent of gastric emptying. This metabolic alteration may drive liver disease progression before hepatic insulin resistance develops.

Section: Diabetes & EndocrinologyMay 1, 2026

Early MASLD Is Associated With Enhanced Oral Glucose Absorption Independent of Gastric Emptying

Early MASLD Is Associated With Enhanced Oral Glucose Absorption Independent of Gastric Emptying

Stable-isotope OGTT data suggest that early MASLD is linked to higher oral glucose absorption, independent of gastric emptying, with preserved hepatic insulin suppression but impaired peripheral glucose clearance.

Section: Diabetes & EndocrinologyMay 1, 2026

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes

A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.

Section: Diabetes & EndocrinologyApr 26, 2026

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

Validating the Virtual Biopsy: Noninvasive Surrogate Endpoints for Disease Progression and Treatment Efficacy in MASH

This review synthesizes the evolving landscape of noninvasive tests (NITs) in MASH, detailing their role as surrogate endpoints for adverse outcomes and therapeutic response based on recent clinical trials and meta-analyses.

Section: Clinical UpdatesApr 3, 2026

Telemedicine-Delivered Nutritional Therapy Slashes Risk of Advanced Liver Disease in Patients with Metabolic Dysfunction

Telemedicine-Delivered Nutritional Therapy Slashes Risk of Advanced Liver Disease in Patients with Metabolic Dysfunction

A large-scale retrospective study demonstrates that individualized carbohydrate reduction through remote care significantly reduces the incidence of MASH and advanced liver complications in patients with type 2 diabetes and obesity compared

Section: Diabetes & EndocrinologyMar 18, 2026

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health

Navigating the New Frontier of MASLD: An Updated Clinical Pathway for Liver Health

This article summarizes the updated clinical care pathway for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting new diagnostic nomenclature, risk stratification tools, and the integration of the first FDA-approv

Section: Diabetes & EndocrinologyMar 13, 2026

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort

The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the main finding

Section: GastroenterologyFeb 17, 2026

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD

The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont

Section: Diabetes & EndocrinologyJan 25, 2026

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

Adherence to the Planetary Health Diet Index Significantly Lowers MASLD Risk: A Global and Individual-Level Analysis

A comprehensive study integrating global and individual data reveals that adherence to the Planetary Health Diet Index (PHDI) provides significant protection against metabolic dysfunction-associated steatotic liver disease (MASLD), highligh

Section: GastroenterologyJan 11, 2026

The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth

The Double-Win Diet: How the Planetary Health Index Protects Your Liver and the Earth

This article explores the groundbreaking link between the Planetary Health Diet Index (PHDI) and reduced risks of metabolic dysfunction-associated steatotic liver disease (MASLD), offering evidence-based insights for personal health and env

Section: GastroenterologyJan 11, 2026

Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial

Healthy Nordic Diet vs. Anti-Lipogenic High-Fat Diet: Superior Cardiometabolic Outcomes in the NAFLDiet Trial

The NAFLDiet trial reveals that while both anti-lipogenic LCPUFA and Healthy Nordic Diets reduce liver fat, the Nordic diet offers superior benefits for weight loss, glycemic control, and systemic inflammation in patients with type 2 diabet

Section: Diabetes & EndocrinologyJan 11, 2026

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall

Section: Diabetes & EndocrinologyJan 7, 2026

Tỷ lệ mắc xơ gan ở các nhóm kinh tế và nhân khẩu học tại Thụy Điển: Một nghiên cứu quần thể dựa trên đăng ký và bối cảnh toàn cầu

Tỷ lệ mắc xơ gan ở các nhóm kinh tế và nhân khẩu học tại Thụy Điển: Một nghiên cứu quần thể dựa trên đăng ký và bối cảnh toàn cầu

Bài đánh giá này tổng hợp các bằng chứng về sự gia tăng tỷ lệ mắc xơ gan ở Thụy Điển, nhấn mạnh sự chênh lệch kinh tế xã hội rõ rệt, đặc biệt là trong xơ gan liên quan đến bệnh gan do rượu (ALD) và bệnh gan mỡ liên quan đến rối loạn chuyển

Section: newsNov 24, 2025

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

Cirrhosis Incidence Across Socioeconomic and Demographic Groups in Sweden: A Register-Based Cohort Study and Its Global Context

This review synthesizes evidence on rising cirrhosis incidence in Sweden, highlighting marked socioeconomic disparities particularly in ALD- and MASLD-related cirrhosis, with broader implications across high-income countries for targeted pr

Section: Clinical UpdatesNov 24, 2025

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

GLP‑1 Receptor Agonists Associated with Lower Fibrosis Progression in MASLD and T2DM: Target‑Trial Emulation of Real‑World Data

A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.

Section: Diabetes & EndocrinologyNov 23, 2025

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

SGLT2 Inhibitors Linked to Lower Fibrosis Progression than DPP‑4 Inhibitors in MASLD with T2DM: Target‑Trial Emulation of Real‑World Cohorts

A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑intermed

Section: Diabetes & EndocrinologyNov 17, 2025

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint

Section: Diabetes & EndocrinologyNov 15, 2025

Prev 1 2 3 Next